Incyte Outlines Post-JAKAFI Diversification Plan with $4B Sales Target

What happened

Incyte executives outlined a plan to grow the non-JAKAFI portfolio to offset the eventual loss of exclusivity for JAKAFI, targeting $4B in sales from newer products while advancing a broader late-stage pipeline. The strategy aligns with the company's existing diversification efforts, which already show momentum with Opzelura up 20% year-over-year in Q1 2026 and the hematology-oncology portfolio up 116%. However, JAKAFI still generated $3.09B in 2025 versus Opzelura's $678.5M, leaving a large gap to close before patent expiry. The news does not materially change the investment picture; the DeepValue master report rates INCY a WAIT with a base-case value of $120 versus the current price of $117.2. Key upcoming catalysts include Q2 earnings on July 28, European Commission approval for Opzelura in atopic dermatitis, and pivotal data for ruxolitinib cream in hidradenitis suppurativa.

Implication

Over the next 6-12 months, Incyte must demonstrate that Opzelura's revenue acceleration is driven by increased prescriptions and market share, not just improved gross-to-net pricing from the CMS settlement. Successful EU launch and continued high growth in the non-JAKAFI portfolio would support a higher valuation, while any stumbles could re-ignite concerns about the 2028 JAKAFI patent cliff. Investors should monitor Q2 and Q3 earnings for clarity on underlying trends and consider adding only on pullbacks below $105 or after confirmed operational momentum.

Thesis delta

No change. The news reinforces management's post-JAKAFI growth strategy but does not provide new evidence of successful execution. The WAIT rating remains appropriate at current price levels.